Capivasertib/Fulvestrant Continues to Elicit Long-Term PFS Benefits in PIK3CA/AKT1/PTEN-Altered HR+/HER2– Breast Cancer
Dato-DXd Reduces High-Grade TRAEs vs Chemo in Pretreated, HR+/HER2– Advanced Breast Cancer
Vepdegestrant Plus Palbociclib Sustains Efficacy in Advanced ER+ Breast Cancer
Atezolizumab Plus Chemo Misses Mark in Early-Relapsing Unresectable TNBC